2009
DOI: 10.1590/s0100-879x2009000300005
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Allogeneic hematopoietic stem cell transplantation (AHSCT) is the treatment of choice for young patients with severe aplastic anemia (SAA). The association of antithymocyte globulin (ATG) and cyclophosphamide (CY) is the most frequently used conditioning regimen for this disease. We performed this retrospective study in order to compare the outcomes of HLA-matched sibling donor AHSCT in 41 patients with SAA receiving cyclophosphamide plus ATG (ATG-CY, N = 17) or cyclophosphamide plus busulfan (BU-CY, N = 24). … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2011
2011
2018
2018

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 20 publications
0
2
0
Order By: Relevance
“…Results of this study are similar to others that also reported presence of higher percentages of donor cells in myeloablative regimens. 16 , 17 Frequencies of chimerism between 51% and 90% donor cells were twice as high in patients who received CY alone (20%) compared to those treated with CY + BUS (10%). Our result is similar to Gomez et al, 18 Jillella et al 19 and Shamshad 20 who also found higher frequencies of mixed chimerism in patients with non-myeloablative conditioning.…”
Section: Discussionmentioning
confidence: 99%
“…Results of this study are similar to others that also reported presence of higher percentages of donor cells in myeloablative regimens. 16 , 17 Frequencies of chimerism between 51% and 90% donor cells were twice as high in patients who received CY alone (20%) compared to those treated with CY + BUS (10%). Our result is similar to Gomez et al, 18 Jillella et al 19 and Shamshad 20 who also found higher frequencies of mixed chimerism in patients with non-myeloablative conditioning.…”
Section: Discussionmentioning
confidence: 99%
“…AHSCT is the treatment of choice for young adults with severe aplastic anemia (SAA), with cure ranging from 75 to 80% and overall survival at 6 years being more than 90%. Cyclophosphamide (CY) plus antithymocyte globulin (ATG) is the most commonly used regimen in AHSCT for SAA due to a low incidence of graft rejection and chronic graft-versus-host disease (GVHD) (1). However, 5-15% of SAA patients receiving sibling AHSCT are likely to develop graft rejection, particularly those patients that have been heavily transfused (2).…”
Section: Introductionmentioning
confidence: 99%